{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-25-000078","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2025-04-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.626543+00:00","generated_at":"2026-05-23T10:27:21.791962+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Immunovant appoints new CEO/CFO, expands IMVT-1402 into Sjögren's and CLE","bullets":["CEO Peter Salzmann retired; Eric Venker (Roivant President) appointed CEO, effective April 21.","CFO Renee Barnett stepped down; Tiago Girao appointed CFO with $481K salary and $6.66M equity award.","Board changes: George Migausky resigned; Robert Susman and Jacob Bauer appointed as directors.","IMVT-1402 IND cleared for potential registrational study in Sjögren's disease, start summer 2025.","Proof-of-concept study in Cutaneous Lupus Erythematosus initiated; cash runway through Graves' readout in 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-25-000078","json":"https://secwatch.observer/filing/0001764013-25-000078.json","markdown":"https://secwatch.observer/filing/0001764013-25-000078.md","text":"https://secwatch.observer/filing/0001764013-25-000078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000078/0001764013-25-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000078/imvt-20250418.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T10:27:21.791962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b6ebcf8ef","claim":"Peter Salzmann retired as Member of Board of Directors at Immunovant, Inc..","evidence_excerpt":"and as a member of the Company’s Board of Directors (the “Board”), effective April 18, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000078/0001764013-25-000078-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Member of Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"2c18063280","claim":"Robert Susman was appointed as Member of Board of Directors at Immunovant, Inc..","evidence_excerpt":"the Board appointed Robert Susman and Jacob Bauer to fill the vacancies on the Board created by the departure of each of Dr. Salzmann and Mr. Migausky","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000078/0001764013-25-000078-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Member of Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"a4df0f0ea9","claim":"Jacob Bauer was appointed as Member of Board of Directors at Immunovant, Inc..","evidence_excerpt":"the Board appointed Robert Susman and Jacob Bauer to fill the vacancies on the Board created by the departure of each of Dr. Salzmann and Mr. Migausky","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000078/0001764013-25-000078-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Member of Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"b555534c30","claim":"Peter Salzmann retired as Chief Executive Officer at Immunovant, Inc..","evidence_excerpt":"Peter Salzmann, M.D. retired from his roles as the Chief Executive Officer and principal executive officer of Immunovant, Inc. (the \"Company\" or \"Immunovant\"), effective April 20, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000078/0001764013-25-000078-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"c9492eccce","claim":"George Migausky resigned as Member of Board of Directors at Immunovant, Inc..","evidence_excerpt":"On April 18, 2025, George Migausky, a member of Immunovant’s Board and Chair of the Audit Committee of the Board (the “Audit Committee”), resigned from the Board and the Audit Committee, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000078/0001764013-25-000078-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Member of Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"f1ae65257e","claim":"Renee Barnett departed as Chief Financial Officer at Immunovant, Inc..","evidence_excerpt":"Also effective April 20, 2025, Renee Barnett ceased serving as the Chief Financial Officer (including the principal financial officer and principal accounting officer) of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000078/0001764013-25-000078-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}